IRBM’s Chief Science Officer, Carlo Toniatti is featured in the Medicine Maker’s Power List

Lessons Learned With Carlo Toniatti

IRBM’s Chief Science Officer, Carlo Toniatti is featured in the Medicine Maker’s Power List

Carlo joins other leading authorities in drug discovery and development as part of the Biopharmaceuticals category in the Medicine Maker Power List. In his interview he reviews future trends in drug development and some of the defining moments of his career.

Read the article in full here

IRBM EDITORIAL

Related Posts

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
In the last few years macrocyclic peptides have emerged as a better class of lead candidates for inhibition of protein-protein interactions with respect to conventional small molecules. The IRBM peptide chemistry team collaborated with the teams at Merck & co. and RaPharma to develop potent macrocyclic peptide inhibitors of PCSK9 a key regulator of plasma LDL-cholesterol.
Back To Top